交银国际研究 行业更新 行业评级 领先 即时零售补贴加大拖累短期利润，估值触底，推荐阿里>京东>美团 日单持续突破。3 季度即时零售平台加大补贴力度，继 7 月 5 日美团即时 零售宣布当日订单突破 1.2 亿（其中餐饮超 1 亿单）、7 月 7 日淘宝闪购日 订单超 8000 万（其中非餐饮订单 1300 万）后，7 月 12 日美团即时零售订 单突破 1.5 亿。参考过去 5 年日单均值/峰值比例下降趋势，考虑到本次峰 值突破相比往年花费更高的补贴投入，我们按美团外卖当季日均单量/峰 值比例约 65%，估算 2 季度美团即时零售/淘宝闪购（含饿了么）/京东外 卖 日 均 单 量 分 别 为 7700/5500/1100 万 单 ， 3 季 度 或 分 别 达 到 8800/6500/1800 万单。 长期来看，补贴收窄后单量稳定及 AOV 趋势仍有不确定性，短期补贴持 续加大将拖累今年内的利润表现： 2025 年 7 月 21 日 互联网行业 行业与大盘一年趋势图 资料来源： FactSet 7/24 11/24 3/25 7/25 -15% -10% -5% 0% 5% 10% 15% 20% 25% ...

Group 1: China Biopharmaceutical (1177 HK) - The company announced a proposed acquisition of 95.09% of Lixin Pharmaceutical for a transaction price of up to $951 million, with a net payment of approximately $501 million after accounting for Lixin's estimated cash and bank deposits of $450 million on the closing date [1][2] - The acquisition will integrate Lixin's four differentiated technology platforms and eight clinical-stage drug candidates, including PD-1/VEGF bispecific antibody and GPRC5D ADC, which have licensing agreements with Merck and AstraZeneca totaling $4 billion [2] - The target price has been raised to HKD 8.00 based on the acquisition and cost reduction efforts, reflecting a potential upside of 17.3% [1][2] Group 2: Flat Glass (6865 HK) - The company expects a significant quarter-on-quarter increase in earnings for 1H25, with a projected profit of RMB 230-280 million, and a midpoint increase of 41% for 2Q25 [3] - The photovoltaic glass industry has seen substantial production cuts since June, with inventory accumulation slowing down, and prices are expected to bottom out and recover starting in August [3] - The target price has been slightly adjusted to HKD 11.45 due to the weaker-than-expected price trends, maintaining a buy rating [3] Group 3: Securities Industry - The securities industry is experiencing strong growth in earnings, with a projected year-on-year increase of 65%-80% for the first half of 2025, averaging a growth of 72% [6][7] - The brokerage business is expected to rebound significantly due to a low base from the previous year, with self-investment income being a major driver of profit growth [6] - The sector's valuation remains attractive, with the A-share securities industry index trading at a price-to-book ratio of 1.38, indicating potential for further valuation increases supported by strong earnings growth [6]

Investment Rating - The investment rating for the company is "Buy" [4][10]. Core Views - The company is expected to see a significant quarter-on-quarter increase in performance for Q2, with estimated earnings of RMB 230-280 million for 1H25, and RMB 120-170 million for Q2, representing a 41% increase from the previous quarter [2][7]. - The report anticipates a recovery in product prices following substantial industry production cuts, which are expected to lead to a bottoming out of prices for photovoltaic glass [7][8]. - The company has a production capacity of 2,000 tons of photovoltaic glass in Vietnam, which is significant for exports to the U.S. The report suggests monitoring the progress of trade agreements between the U.S. and Vietnam, as a reduction in tariffs could benefit the company's operations [7][8]. - The report maintains a positive outlook on the photovoltaic supply side, citing recent government meetings aimed at regulating the industry and promoting the exit of outdated production capacity [7][8]. Financial Overview - Revenue projections for the company are as follows: RMB 21,524 million in 2023, RMB 18,683 million in 2024, RMB 16,543 million in 2025E, RMB 20,822 million in 2026E, and RMB 23,232 million in 2027E, with a year-on-year growth of 39.2% in 2023, followed by declines in 2024 and 2025, and recoveries in subsequent years [3][11]. - Net profit is projected to be RMB 2,760 million in 2023, dropping to RMB 1,007 million in 2024, and further to RMB 340 million in 2025E, before rebounding to RMB 1,828 million in 2026E and RMB 2,368 million in 2027E [3][11]. - The earnings per share (EPS) are expected to be RMB 1.17 in 2023, decreasing to RMB 0.43 in 2024, and RMB 0.15 in 2025E, with a significant recovery anticipated in 2026E and 2027E [3][11]. - The price-to-earnings (P/E) ratio is projected to be 7.8 in 2023, increasing to 21.2 in 2024, and then to 62.6 in 2025E, before stabilizing in the following years [3][11]. Market Performance - The company's stock price has shown a year-to-date change of -8.88%, with a 52-week high of HKD 15.84 and a low of HKD 7.75 [6][10]. - The average daily trading volume is reported at 10.68 million shares [6].

Industry Rating - The report maintains a "Leading" investment rating for the securities industry, indicating strong growth potential and favorable market conditions [1]. Core Insights - The report highlights a robust growth in Q2 earnings for the securities industry, with a year-on-year profit increase of 65%-80% for A-share listed brokers, averaging 72% [4][5]. - The average daily trading volume in A-shares for H1 2025 reached 1.36 trillion RMB, reflecting a year-on-year growth of 58.8% [4]. - The report emphasizes that the current valuation of the securities sector remains attractive, with the A-share securities industry index trading at a price-to-book ratio of 1.38, below the historical median of 1.52 [4]. Valuation Summary - The report provides a detailed valuation overview for key companies in the securities sector, including: - CITIC Securities (6030 HK): Buy rating, target price of 30.00 HKD, current price 25.65 HKD, with a potential upside of 17.0% [2][17]. - Huatai Securities (6886 HK): Buy rating, target price of 20.00 HKD, current price 16.40 HKD, with a potential upside of 22.0% [2][31]. - CICC (3908 HK): Buy rating, target price of 22.00 HKD, current price 18.94 HKD, with a potential upside of 16.2% [2][17]. - CITIC Construction Investment (6066 HK): Buy rating, target price of 14.00 HKD, current price 11.80 HKD, with a potential upside of 18.6% [2][17]. Performance Trends - The report notes that the performance of the securities industry has significantly improved compared to the previous year, with major indices showing positive trends [3][12]. - The report indicates that the IPO fundraising in A-shares has seen a recovery, with a total of 374 million RMB raised in H1 2025, marking a 15% year-on-year increase [4][10]. Financial Forecasts - The report projects a 19% year-on-year growth in overall profits for the securities industry in 2025, driven by favorable market conditions and strong performance from leading brokers [4][19]. - Specific forecasts for CITIC Securities include a projected net profit of 25.8 billion RMB for 2025, reflecting an 18.9% increase from the previous year [21][28]. Conclusion - The report concludes that the securities industry is well-positioned for continued growth, supported by strong earnings, favorable market conditions, and attractive valuations, maintaining a positive outlook for key players in the sector [4][19].

Investment Rating - The report assigns a "Buy" rating to China Biologic Products (1177 HK) with a target price of HKD 8.00, indicating a potential upside of 17.3% from the current price of HKD 6.82 [4][10][15]. Core Insights - The acquisition of Lixin Pharmaceutical for USD 5 billion is expected to enhance the company's differentiated pipeline assets and technology platforms, leading to an upward revision of the target price [2][7]. - The integration of Lixin's four unique technology platforms is anticipated to accelerate the development of China Biologic's self-researched products, with significant potential contributions to revenue growth [7][10]. - The report highlights that Lixin has eight drug candidates in clinical stages, including promising candidates with licensing agreements worth up to USD 4 billion with major pharmaceutical companies [7][10]. Financial Overview - Revenue projections for China Biologic Products are as follows: - 2023: RMB 26,199 million - 2024: RMB 28,866 million - 2025E: RMB 34,175 million (growth of 18.4%) - 2026E: RMB 38,706 million (growth of 13.3%) - 2027E: RMB 43,606 million (growth of 12.7%) [3][16]. - Net profit estimates are projected to increase from RMB 2,332 million in 2023 to RMB 5,340 million by 2027, reflecting a significant growth trajectory [3][16]. - The report also notes an adjustment in the net profit forecast for 2025-2027, with an increase of 6-10% due to cost reduction efforts [7][9]. Valuation Model - The DCF valuation model estimates the equity value of China Biologic Products at HKD 8.00 per share, based on projected free cash flows and a perpetual growth rate of 2% [10][11]. - The enterprise value is calculated at RMB 152,132 million, with a net cash position of RMB 2,478 million [10][11]. Market Performance - The stock has shown a year-to-date increase of 113.13%, with a 52-week high of HKD 6.82 and a low of HKD 2.73 [6][10].

Group 1: Company Overview - TSMC's management has raised its full-year revenue growth guidance from approximately 25% to 30% year-on-year, indicating strong resilience in gross margin at 58.6%, surpassing previous expectations [1][2] - The company anticipates that the demand for AI chips will increase due to the U.S. government's relaxation of export restrictions, which is expected to drive the demand for advanced process technologies [2] - TSMC plans to ramp up production of its 2nm process technology in the second half of 2025, with expectations that the volume of 2nm wafers will exceed that of 3nm and 5nm wafers during the same period [2] Group 2: Financial Projections - The target price for TSMC has been raised to $280, reflecting a potential upside of 17.9% from the closing price of $237.56, based on a 26x average P/E ratio for 2025/26 [1][2] - Adjustments to earnings per share (EPS) estimates have been made, with new projections set at 59.5 and 65.5 New Taiwan Dollars, down from previous estimates of 60.8 and 69.6 New Taiwan Dollars [2] Group 3: Market Context - The report highlights that the recovery in consumer electronics is expected to be moderate due to trade uncertainties, but the high demand for AI is likely to sustain TSMC's pricing for 3nm and 5nm technologies [2] - The global semiconductor market is projected to see 30% of its capacity in processes below 2nm being produced in the U.S. in the long term [2]

Group 1: Anta Sports Products (2020 HK) - The second quarter revenue met expectations, with management reaffirming the annual guidance for 2025, indicating low single-digit, mid single-digit, and 50-55% year-on-year revenue growth for Anta, FILA, and other brands respectively [3] - Despite intense industry competition, management maintains growth guidance for all brands, expecting high single-digit, mid single-digit, and over 30% year-on-year growth for Anta, FILA, and other brands respectively [3] - The forecast for net profit from 2025 to 2027 is projected to be between RMB 13.41 billion and RMB 16.54 billion, with a target price of HKD 110.20 based on a 20x P/E ratio for 2026, maintaining a buy rating [3][4] Group 2: Junda Co., Ltd. (002865 CH) - The company expects a loss of RMB 0.94 billion to RMB 1.94 billion in Q2 2025, which is an increase from the loss of RMB 1.06 billion in Q1 2025, primarily due to a decline in battery prices following a surge in installations in mainland China [5] - Junda has signed a strategic cooperation agreement with Turkey and Europe's largest photovoltaic module manufacturer to jointly build a solar cell production base with a capacity of up to 5GW [5] - The outlook remains positive for the company, anticipating a turnaround in performance in 2026 driven by the commencement of production in Oman and supply-side reforms [5] Group 3: E-commerce Industry - In Q2 2025, adjusted year-on-year growth for physical e-commerce retail sales was 6.3%, with categories like home appliances and cosmetics experiencing a decline in growth [7] - E-commerce platforms are increasing investments in instant retail to drive cross-selling with traditional shelf e-commerce, enhancing user engagement [7] - Major players like Alibaba and JD.com are expected to maintain double-digit year-on-year growth, although profitability may be pressured due to increased investments in flash sales and delivery services [8] Group 4: Economic Data Insights - The consumer price index for June is expected to show a month-on-month increase of 0.30% in both the US and China, with the previous data being 0.10% [9] - The industrial product factory price index is anticipated to rise by 0.20% year-on-year in the US for June [9]

Investment Rating - The investment rating for the company is "Buy" [2][8]. Core Insights - The company has released a performance forecast indicating a loss of 200-300 million RMB for 1H25, which aligns with market expectations due to a decline in battery prices following a surge in installations in mainland China [6]. - The company has signed a strategic cooperation agreement with Schmid Pekintaş Energy to establish a 5GW solar cell production base in Turkey, which is expected to enhance its overseas capacity and market presence [6]. - Recent government meetings suggest a potential turnaround in the solar supply side, with material prices beginning to recover [6]. Financial Overview - Revenue projections for the company are as follows: 2023: 18,657 million RMB, 2024: 9,952 million RMB, 2025E: 8,431 million RMB, 2026E: 13,874 million RMB, 2027E: 15,397 million RMB, with a significant year-on-year growth of 60.9% in 2023 followed by a decline in subsequent years [5][11]. - Net profit forecasts show a loss in 2024 and 2025E, with expected profits of 1,427 million RMB in 2026 and 1,726 million RMB in 2027 [5][11]. - The company's earnings per share (EPS) are projected to be 3.59 RMB in 2023, dropping to -2.58 RMB in 2024, and recovering to 4.88 RMB in 2026 and 5.90 RMB in 2027 [5][11]. Valuation Metrics - The target price for the company has been adjusted to 49.82 RMB, reflecting a 10.2x price-to-earnings ratio for 2026 [6][7]. - The company’s market capitalization is approximately 9,538.81 million RMB, with a 52-week high of 80.40 RMB and a low of 34.80 RMB [4][6]. Market Position - The company has a significant overseas revenue contribution, accounting for 51.9% in 1H25, although this is a decrease from 58% in 1Q25 [6]. - The strategic move to establish a production base in Turkey is aimed at capturing local market opportunities and facilitating exports to higher-priced markets like the USA [6].

Investment Rating - The report assigns a "Buy" rating to major companies in the e-commerce sector, including Alibaba, JD.com, Pinduoduo, and Kuaishou [2][3]. Core Insights - The e-commerce industry is experiencing accelerated growth in Q2 2025, with online retail sales of physical goods showing a year-on-year increase of 6.3%, up from 5.7% in Q1 [1][3]. - Instant retail is a key investment theme, with major platforms increasing their investments to drive high-frequency consumption and cross-selling opportunities [3]. - The report anticipates continued growth trends in the industry, with specific expectations for Alibaba, JD.com, Pinduoduo, and Kuaishou regarding their performance and profitability [3]. Summary by Sections E-commerce Growth - In Q2 2025, the online retail sales of physical goods are projected to maintain a year-on-year double-digit growth, benefiting from improved penetration and technology service fees [3]. - The report highlights that the demand for home decoration is recovering, with furniture sales growing by 29% year-on-year [1]. Company Performance - Alibaba's daily peak orders for its flash purchase service exceeded 80 million, with a DAU surpassing 200 million, reflecting a week-on-week growth of 15% [3]. - JD.com reported that nearly 200 restaurant brands achieved sales of over one million, launching a "Double Hundred Plan" to support more brands [3]. - Pinduoduo plans to launch instant delivery services in select first-tier cities, focusing on high-frequency categories like fresh produce and fast-moving consumer goods [3]. Market Outlook - The report projects that the overall e-commerce market GMV will grow by 5% year-on-year in 2025 [11]. - The logistics sector is also expected to see growth, with the postal bureau estimating a 19% year-on-year increase in express delivery volume for the first half of 2025 [9].

交银国际研究 每日晨报 2025 年 7 月 16 日 今日焦点 | 中国宏观 | | | --- | --- | | 上半年新旧动能加速切换，内外需平衡改善 | 宏观策略 | | 李少金 Evan.Li@bocomgroup.com | | 中国内地 2025 年上半年 GDP 同比增长 5.3%，其中 2 季度同比增长 5.2%， 较 1 季度的 5.4%稍有放缓但整体运行保持在合理区间，这一表现在全球 经济增长扰动加大的背景下显得尤为珍贵。从增长贡献及对比 1 季度来 看，2 季度消费（52.3% vs 51.7%）、投资（24.7% vs 8.7%）、净出口 （23% vs 39.5%）三大需求的协调性较 1 季度明显改善，内需贡献增长， 而外需依然韧性，特别是在外部贸易紧张环境下，出口强劲表现成为稳 增长的关键支撑力量，也凸显了中国制造业的全球竞争优势和强大弹性。 6 月当月数据仍呈分化态势：工业生产加速至 6.8%，消费增速回落至 4.8%，投资增速放缓趋势延续，主要反映短期扰动因素对经济走势的影 响，经济运行的波浪式特征依然存在。 综合看，上半年中国经济在复杂的外部环境下展现较强韧性，新旧动能 ...